Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Commissioning of a Commercial Secondary Dose Check Software and Clinical Implementation for the Magnetic Resonance-guided Linear Accelerator Adaptive Workflow.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Medknow Publications Country of Publication: India NLM ID: 9441104 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0971-6203 (Print) Linking ISSN: 09716203 NLM ISO Abbreviation: J Med Phys Subsets: PubMed not MEDLINE
    • Publication Information:
      Publication: Mumbai : Medknow Publications
      Original Publication: Bombay : The Association, [1994-
    • Abstract:
      Competing Interests: There are no conflicts of interest.
      Purpose: The purpose of this study was to report the commissioning the secondary dose calculation software ThinkQA (TQA) for an magnetic resonance-guided linear accelerator (MR-linac).
      Methods: The Medical Physics Practice Guideline 5.a. (MPPG5a) tests, and dose in inhomogeneities, beam profiles, and depth dose curves were calculated and compared between Monaco and TQA. Five intensity modulated radiotherapy (IMRT) plans (anal, abdominal, head and neck, prostate, and lung), based on TG-244 guidelines were evaluated varying the gamma criteria. Furthermore, the initial and adapted plans for the first session for 17 patients in different anatomical regions were calculated in TQA using different gamma criteria. For five patients, six measurements were made at different fractions using ArcCheck and compared with TQA.
      Results: The majority of tests met the tolerances defined in the MPPG5a with the exception of dose profiles (>10%), and large multileaf collimator-shaped fields with extensive blocking (>2%). For the IMRT plans, tight criteria such as 2%/2 mm may not be suitable for all scenarios. Thus, we adopt a reasonable 3%/2 mm without compromising the quality of the plan that included significant high-to-low-density interfaces. It is observed that, the values obtained for clinical cases are in the range from 94.6% to 99.8% (TQA), 97.0% to 99.6% (ArcCheck), except in a prostate case with 87.8% (TQA) and 99.3% (ArcCheck).
      Conclusion: We commissioned TQA as a secondary dose calculation for MR-linac and we introduced it clinically for adaptive treatment workflow using 3%/2 mm with 95% as tolerance limit and 90% as action limit.
      (Copyright: © 2025 Journal of Medical Physics.)
    • References:
      Med Phys. 2009 Nov;36(11):5359-73. (PMID: 19994544)
      Phys Med Biol. 2021 Mar 01;66(5):05TR02. (PMID: 32570225)
      Med Phys. 2009 Nov;36(11):5261-91. (PMID: 19994536)
      Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1205-1216. (PMID: 36922083)
      Med Phys. 2018 Apr;45(4):e53-e83. (PMID: 29443390)
      Med Phys. 2009 Sep;36(9):4197-212. (PMID: 19810494)
      J Med Phys. 2024 Apr-Jun;49(2):213-224. (PMID: 39131419)
      Med Phys. 2021 Oct;48(10):e808-e829. (PMID: 34213772)
      J Appl Clin Med Phys. 2015 Sep 08;16(5):14–34. (PMID: 26699330)
      J Appl Clin Med Phys. 2019 Dec;20(12):54-62. (PMID: 31722133)
      Med Phys. 2016 Apr;43(4):1713. (PMID: 27036569)
      J Appl Clin Med Phys. 2020 Jul;21(7):160-172. (PMID: 32432405)
      Phys Med Biol. 2007 Dec 7;52(23):7045-54. (PMID: 18029992)
      J Appl Clin Med Phys. 2021 Apr;22(4):52-62. (PMID: 33735491)
      Phys Med Biol. 2005 Apr 7;50(7):1363-76. (PMID: 15798329)
    • Contributed Indexing:
      Keywords: Adaptive; IMRT; QA; magnetic resonance-guided linear accelerator; secondary dose check
    • Publication Date:
      Date Created: 20250421 Latest Revision: 20250422
    • Publication Date:
      20250422
    • Accession Number:
      PMC12005651
    • Accession Number:
      10.4103/jmp.jmp_150_24
    • Accession Number:
      40256178